Pluristem Therapeutics Inc.
PSTI · NASDAQ
6/30/2025 | 6/30/2021 | 6/30/2020 | 6/30/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.21 | 0.13 | -0.13 |
| FCF Yield | -31.29% | -28.10% | -16.56% | -40.81% |
| EV / EBITDA | -2.75 | -2.16 | -5.63 | -2.05 |
| Quality | ||||
| ROIC | 154.69% | -61.25% | -51.22% | -154.45% |
| Gross Margin | 48.95% | 0.00% | 100.00% | 96.30% |
| Cash Conversion Ratio | 0.78 | 0.62 | 0.90 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | 287.28% | -100.00% | -22.81% | – |
| Free Cash Flow Growth | 0.00% | -17.43% | 10.28% | -36.69% |
| Safety | ||||
| Net Debt / EBITDA | -0.04 | 0.14 | 0.24 | 0.12 |
| Interest Coverage | -26.72 | -649.01 | -150.39 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -711.27 | 0.00 | 25,550.00 | -406,677.59 |